PMID- 19525193
OWN - NLM
STAT- MEDLINE
DCOM- 20090825
LR  - 20090615
IS  - 1938-0712 (Electronic)
IS  - 1557-9190 (Linking)
VI  - 9
IP  - 3
DP  - 2009 Jun
TI  - Urinary findings in renal light chain-derived amyloidosis and light chain 
      deposition disease.
PG  - 234-8
LID - 10.3816/CLM.2009.n.046 [doi]
AB  - BACKGROUND: Early recognition of light chain-derived (AL) amyloidosis and light 
      chain deposition disease (LCDD) is essential for optimal therapy. However, 
      clinical and laboratory manifestations of these unusual conditions often go 
      unrecognized. Renal protein deposits in AL amyloidosis and LCDD can cause both 
      heavy albuminuria and Bence Jones proteinuria. Absent separate etiologies, this 
      combined finding is rare and provides a clue to the diagnosis of these 
      conditions. MATERIALS AND METHODS: We retrospectively reviewed test results of 
      urine immunoelectrophoreses and urine immunofixation electrophoreses performed at 
      a single institution from 1977 to 2006. Patients with both heavy albuminuria and 
      Bence Jones proteinuria were investigated further to determine whether these 
      findings were predictive of renal AL amyloidosis or LCDD. We reviewed the 
      patients' clinical histories, laboratory data, and pathology reports and included 
      patients with biopsy-confirmed renal AL amyloidosis or LCDD in this series. 
      RESULTS: We identified 6 patients with renal amyloidosis or LCDD who presented 
      with the dual findings of Bence Jones proteinuria and heavy albuminuria. We 
      report their demographic information, laboratory data, and case histories. 
      CONCLUSION: The simultaneous presence of heavy albuminuria and Bence Jones 
      proteinuria justifies a workup for AL amyloidosis or LCDD. Prompt recognition of 
      these rare conditions would permit earlier initiation of therapy and potentially 
      limit organ dysfunction. In addition, patients might be spared unnecessary 
      clinical investigation and unwarranted treatment.
FAU - Melmed, Gavin M
AU  - Melmed GM
AD  - Department of Medical Oncology, Baylor Medical Center at Garland, TX 75042, USA. 
      gavinm@baylorhealth.edu
FAU - Fenves, Andrew Z
AU  - Fenves AZ
FAU - Stone, Marvin J
AU  - Stone MJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Lymphoma Myeloma
JT  - Clinical lymphoma & myeloma
JID - 101256500
RN  - 9006-99-9 (Bence Jones Protein)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Albuminuria/urine
MH  - Amyloidosis/diagnosis/*urine
MH  - Bence Jones Protein/urine
MH  - Diagnosis, Differential
MH  - Female
MH  - Humans
MH  - Immunoelectrophoresis/methods
MH  - Kidney Diseases/*urine
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/complications
MH  - Retrospective Studies
MH  - Treatment Outcome
EDAT- 2009/06/16 09:00
MHDA- 2009/08/26 09:00
CRDT- 2009/06/16 09:00
PHST- 2009/06/16 09:00 [entrez]
PHST- 2009/06/16 09:00 [pubmed]
PHST- 2009/08/26 09:00 [medline]
AID - S1557-9190(11)70198-6 [pii]
AID - 10.3816/CLM.2009.n.046 [doi]
PST - ppublish
SO  - Clin Lymphoma Myeloma. 2009 Jun;9(3):234-8. doi: 10.3816/CLM.2009.n.046.